GE HealthCare AS Korea
- Address: 15th Floor, Seoul Square, 416 Hangang-daero, Jung-gu, Seoul, South Korea
- Website: www.gehealthcare.co.kr/
Introduction to GE HealthCare's Pharmaceutical Diagnostics (PDx) Division
GE HealthCare's PDx division is a global leader in developing and manufacturing pharmaceutical imaging agents, supporting over 119 million patient imaging procedures annually. With over 4,000 professionals and seven cGMP manufacturing sites, their products are used in more than 100 countries.
Key Areas of Focus
1) Contrast Media: Enhances imaging clarity in X-ray, MRI, and CT scans.
2) Molecular Imaging: Develops agents for precision care, targeting specific biological processes.
Innovative Products
Recent advancements include Flyrcado™ (flurpiridaz F 18) injection for coronary artery disease diagnosis and a manganese-based MRI contrast agent, offering alternatives to gadolinium-based agents.
Global Impact
Committed to innovation, GE HealthCare's PDx division aims to improve diagnostic accuracy and patient outcomes, shaping the future of diagnostic imaging.
GE HealthCare's PDx division is a global leader in developing and manufacturing pharmaceutical imaging agents, supporting over 119 million patient imaging procedures annually. With over 4,000 professionals and seven cGMP manufacturing sites, their products are used in more than 100 countries.
Key Areas of Focus
1) Contrast Media: Enhances imaging clarity in X-ray, MRI, and CT scans.
2) Molecular Imaging: Develops agents for precision care, targeting specific biological processes.
Innovative Products
Recent advancements include Flyrcado™ (flurpiridaz F 18) injection for coronary artery disease diagnosis and a manganese-based MRI contrast agent, offering alternatives to gadolinium-based agents.
Global Impact
Committed to innovation, GE HealthCare's PDx division aims to improve diagnostic accuracy and patient outcomes, shaping the future of diagnostic imaging.